Common side effects of chemotherapy – thrombocytopenia, the incidence of thrombocytopenia is very low, but drugs such as gemcitabine in the treatment of first-line treatment of advanced lung cancer to establish the status, the incidence of thrombocytopenia has also been increased. If the platelets less than 20X109 / L, platelet transfusion will be carried out, and the formation of anti-platelet antibodies may affect the effect of blood transfusion, platelet filters used clinically to reduce the formation of anti-platelet antibody, or platelets select HLA identical, so the clinical Platelet transfusion and adverse reactions are rare. Transmission frequency of infection after platelets have a decreasing trend.
Common side effects of chemotherapy – thrombocytopenia, the ascending current clinical use of recombinant human platelet drugs interleukin (rh1L-ll) in vitro can promote the formation of clones of megakaryocytes, Bree et al reported two weeks apes application 1L-ll , the platelet tripled. Michael et al 1L-ll's I clinical trial showed that in the end of chemotherapy within 3 – 14 days application of 25 – 50g / (kg d) reduced platelet reduction. 1L-ll of the side effects are edema, fatigue, muscle and joint pain, injection site swelling, etc., and various other cytokines, there is no fever.
Proof of current research: recombinant human interleukin -11 for thrombocytopenia after chemotherapy Peas 50X109 / L of cancer patients has obvious effect of thrombopoietin; help to reduce the cancer patients after chemotherapy, the degree of thrombocytopenia, and can maintain the platelet count steady-state levels, significantly reduced the duration of thrombocytopenia and accelerated the recovery of platelet count. rh1L-ll there is no increase in platelet count and increase in the phenomenon caused by excessive, no cause thrombosis in vivo phenomenon.
Common side effects of chemotherapy – thrombocytopenia, other components of blood such as the WBC, LBC, NBC, as well as blood clotting mechanisms, in particular fibrinogen (Fbg), liver and kidney functions were not affected. rh1L-ll can cause slight reversible decrease of hemoglobin; adverse reactions were mild, mainly nausea, vomiting, fatigue, local pain and dizziness, headache, patients often relieve themselves in the course of treatment can be tolerated. And the use of giant particle dissolution with lml water for injection, subcutaneous injection; bone marrow suppression during chemotherapy, a record that used doses of chemotherapy drugs and may lead to significantly reduced and the lure of blood platelets may be the end of the chemotherapy drugs after 24 – 48 hours from the subcutaneous injection of this product, each time a dose of 25 – 50g, used in conjunction 7_14 days. Patients should be checked during the treatment of peripheral blood platelet count, platelet recovery to 100XIL be above shall be discontinued. High-dose chemotherapy, can be adapted to large doses of this product.